Sentinel Lymph Node Biopsy

SLNB Fundamentals - Node Navigator

• Definition: The first lymph node(s) to receive lymphatic drainage from a primary tumor.
• Purpose: Accurately stages the axilla in early breast cancer; guides decisions on Axillary Lymph Node Dissection (ALND) and adjuvant therapy.
• Technique: Dual method (blue dye + technetium-99m sulfur colloid) is preferred for localization.
  • Injected peritumorally or subareolarly.
  • Identified using a gamma probe and/or visually (blue dye).
• Key Benefit: Avoids routine ALND morbidity (e.g., lymphedema, pain) if SLN is negative.

⭐ For clinically node-negative (cN0) early breast cancer, SLNB is the standard axillary staging procedure.

The SLNB Procedure - Tracer Tactics

• Tracers Used:
  • Dual technique (Gold Standard):
    • Blue Dye: Isosulfan Blue (1%) or Methylene Blue. Injected intraoperatively.
    • Radiocolloid: Technetium-99m ($^{ ext{99m}}$Tc) sulfur colloid / albumin nanocolloid. Injected preoperatively (2-20 hrs).
  • Indocyanine Green (ICG): Emerging near-infrared fluorescent dye.
• Injection Techniques & Volume:
  • Sites: Peritumoral, intradermal (overlying tumor), subareolar (Sappey’s plexus).
  • Volume: Blue dye ~1 mL; Radiocolloid ~0.2-0.5 mL.
• Intraoperative Identification:
  • Gamma probe: Detects radiotracer ("hot" node).
  • Visual: Blue dye stains lymphatics/nodes ("blue" node).
  • Any "hot" or "blue" node is an SLN. Typically 1-4 SLNs removed.

⭐ The dual technique (blue dye + radiocolloid) maximizes SLN identification rates (approaching 98%) with a false negative rate around 5-10%.

Results & Ramifications - Axillary Answers

• SLNB Results:

  • Positive:
    • Macrometastasis (> 2 mm)
    • Micrometastasis (0.2-2 mm)
    • ITCs (≤ 0.2 mm): AJCC N0(i+), often node-negative management.
  • Negative: No ALND. FNR target < 5-10%.

• Management based on SLNB:

• Key Trials:
  • ACOSOG Z0011: For T1/T2 tumors, 1-2 positive SLNs, WBRT planned & no ENE → ALND omission safe.

    ⭐ ACOSOG Z0011 showed no difference in overall survival or locoregional recurrence for omitting ALND in eligible early breast cancer patients.

  • AMAROS: Axillary RT non-inferior to ALND for SLNB+ patients; associated with less lymphedema.

Complications & Contraindications - SLNB Safety Net

• Complications:
  • Seroma (most common), lymphedema (↓ vs ALND)
  • Intercostobrachial nerve injury: pain, numbness
  • Allergic reaction (dye/radiotracer), infection/hematoma
  • Axillary web syndrome, shoulder stiffness
• Contraindications (Absolute):
  • Clinically positive nodes (palpable/biopsy-proven)
  • Inflammatory breast cancer (IBC)
  • Locally advanced breast cancer (LABC)
• Contraindications (Relative):
  • Prior axillary surgery/radiotherapy
  • Pregnancy (radiotracer concern)
  • Multifocal/multicentric disease
• Factors ↑ False Negative Rate (FNR):
  • Surgeon experience (<20 cases)
  • Single tracer use (vs dual)
  • Large tumor, LVI, post-NACT (Neoadjuvant Chemotherapy)

⭐ Dual mapping (blue dye + radiocolloid) is crucial to minimize FNR, especially post-NACT.

High‑Yield Points - ⚡ Biggest Takeaways

• SLNB is standard for axillary staging in clinically node-negative (cN0) invasive breast cancer.
• Dual tracer (blue dye + radiocolloid) is preferred for optimal detection and lower false negative rates.
• A negative SLN avoids axillary lymph node dissection (ALND), significantly reducing morbidity (e.g., lymphedema).
• Key contraindications: inflammatory breast cancer, palpable axillary nodes (cN+), pregnancy (for radiocolloid).
• ACOSOG Z0011 trial impacts management for 1-2 positive SLNs in select patients with breast conserving therapy.